Redeye argues that the changed financial target is relatively unaffecting the long-term case for Sedana Medical. Our estimate changes do not affect our US estimates, which make up a large chunk of the fundamental value. Hence, we only make small changes to our fair value range.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/